The U.S. Food and Drug Administration has launched the final version of its Expedited Investigational New Drug (IND) Pilot Program, opening applications for an initiative designed to shorten the path from drug discovery to the first clinical trial in humans. The agency began accepting applications this week and will keep the window open until October 30, 2026, with the goal of testing whether closer collaboration between regulators, drug sponsors, and research institutions can meaningfully compress a stage of drug development that currently takes up to two years in the United States.
How the Pilot Actually Works
At the center of the pilot is a new collaborative model pairing drug sponsors with what the FDA calls Qualified Research Institutions, or QRIs, third-party organizations such as academic medical centers, health networks, contract research organizations, or regulatory advisors with relevant scientific expertise. Sponsors apply to the program together with a prospective QRI partner, and if selected, the QRI provides iterative, discipline-specific guidance across the three components of a first-in-human IND submission: pharmacology and toxicology, clinical design, and chemistry, manufacturing, and controls.
Rather than requiring sponsors to submit a complete IND package all at once, the pilot introduces a rolling submission model, allowing the FDA to review and accept individual components as they’re completed instead of waiting for the full application. The pilot also encourages sponsors to begin coordinating activities that typically follow IND submission, including institutional review board review and clinical trial site activation, earlier and in parallel with IND preparation rather than only after the FDA clears the application.
Why the FDA Is Doing This Now
The agency’s own framing leans heavily on international competitiveness. The FDA says first-in-human trials can take up to two years to complete in the United States, a timeline it describes as considerably slower than comparable trials completed in China and Australia. The agency has framed that gap as more than a competitiveness problem: when trials move overseas to move faster, American patients lose access to investigational therapies being studied, and the FDA’s own ability to oversee and shape the underlying science diminishes along with it.
The pilot sits within Operation TrialBlazer, a broader Department of Health and Human Services initiative aimed at modernizing clinical research, and follows a directive from the Trump administration prioritizing faster domestic drug development.
“The pilot not only pairs industry innovators with top research institutions to accelerate high-quality data being submitted to the FDA, it also tests if the partnership can accelerate what happens after the FDA allows a clinical trial to proceed.”
— Kyle Diamantas, Acting FDA Commissioner
Who Can Apply and What Happens Next
The FDA expects to select approximately eight to ten sponsor-QRI pairs for the pilot’s initial cohort, with sponsors responsible for submitting the joint application. The agency plans to review applications and announce selected participants by December 18, 2026. Participation is entirely voluntary, and companies not selected for the pilot will retain access to the FDA’s existing early-development mechanisms, including INTERACT meetings and standard pre-IND consultations, meaning the pilot adds a new pathway rather than replacing options already available to drug developers.
What Doesn’t Change
Despite the pilot’s emphasis on speed and collaboration, the FDA has been explicit that its regulatory authority remains fully intact throughout the process. The standard 30-day IND review period still applies, and the agency retains full authority to place a clinical trial protocol on hold if safety or scientific concerns arise, regardless of how closely a sponsor worked with its QRI partner beforehand. The pilot’s central bet is narrower than eliminating regulatory oversight: it’s testing whether earlier, more structured collaboration during IND preparation can catch and resolve problems before formal submission, reducing the odds of a clinical hold rather than reducing FDA scrutiny itself.
That distinction matters for how the pilot should be understood. It isn’t a fast-track approval shortcut so much as an attempt to front-load quality control, moving the kind of back-and-forth that currently happens during FDA review to an earlier stage where a QRI’s specialized expertise can help sponsors get the pharmacology, clinical design, and manufacturing components right the first time.
The Bigger Picture: A Broader Push to Modernize Clinical Trials
The Expedited IND Pilot is one piece of a two-pronged strategy the FDA has laid out for early-stage clinical development. Alongside the pilot, the agency says it’s separately working to refine IND expectations more broadly, aiming to ensure requirements reflect what’s scientifically appropriate for Phase 1 trials and reducing what it describes as over-submission that adds paperwork without a commensurate safety benefit. The FDA has also suggested that lessons from this pilot could eventually inform a formal accreditation model for QRIs, potentially building a recognized, sustainable network of research institutions equipped to support efficient first-in-human development going forward.
That kind of accelerated regulatory pathway mirrors a broader global pattern of medical regulators experimenting with faster approval frameworks. Similar to how India’s parliamentary committee has pushed for streamlined device approval pathways and China has built out AI-specific medical device standards at speed, the FDA’s pilot reflects a shared pressure facing regulators worldwide: balancing genuine safety oversight against the competitive cost of moving too slowly relative to other countries’ regulatory systems.
What Comes Next
For now, the pilot remains an experiment rather than a permanent policy shift. Its outcome, measured in the eight to ten sponsor-QRI pairs selected by December, will generate the evidence the FDA says it needs to decide whether this collaborative model is worth expanding, formalizing through accreditation, or ultimately extending beyond its initial first-in-human trial scope.
[…] health agencies undergoing significant process changes under the current administration, from new FDA pilot programs aimed at reshaping how drug trials get approved to now this proposed restructuring of how NIH itself decides which biomedical research gets funded. […]